Kynurenine Pathway In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The kynurenine pathway (KP) is the principal catabolic route for the essential amino acid tryptophan, accounting for approximately 95% of tryptophan degradation in the body. This metabolic cascade generates a series of neuroactive intermediates—collectively termed kynurenines—that exert profound effects on the central nervous system through modulation of glutamate neurotransmission, oxidative stress, neuroinflammation, and immune signaling. Dysregulation of the kynurenine pathway has been increasingly implicated in the pathogenesis of [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, [Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX--, [amyotrophic lateral sclerosis[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX--, and [multiple sclerosis[/diseases/[multiple-sclerosis[/diseases/[multiple-sclerosis[/diseases/[multiple-sclerosis--TEMP--/diseases)--FIX--, making it a compelling target for neuroprotective therapeutic intervention.
The pathway produces both neuroprotective metabolites (kynurenic acid) and neurotoxic metabolites (quinolinic acid, 3-hydroxykynurenine), and the balance between these branches—governed by cell type-specific enzyme expression in [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX-- and [microglia" title="[Kynurenine Pathway: a possible new mechanism for exercise in the prevention and treatment of Alzheimer's Disease. Front Aging Neurosci (2025]. Frontiers)">2.
- Indoleamine 2,3-dioxygenase 2 (IDO2): Lower catalytic activity than IDO1; expressed in liver, kidney, and brain with a less well-characterized role in neurodegeneration.
- Tryptophan 2,3-dioxygenase (TDO2): Constitutively expressed in the liver and brain; regulated by tryptophan availability and glucocorticoids. TDO2 is upregulated in the [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX-- and [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- of Alzheimer's Disease brains, contributing to local kynurenine production [3].
N-formylkynurenine is rapidly converted to L-kynurenine by kynurenine formamidase. L-kynurenine then serves as the central branch point of the pathway.
L-kynurenine is transaminated by kynurenine aminotransferases (KATs I–IV) to produce kynurenic acid (KYNA). This metabolite is predominantly synthesized by [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX-- and acts as [4]:
- An endogenous antagonist of [NMDA receptor[/entities/[nmda-receptor[/entities/[nmda-receptor[/entities/[nmda-receptor--TEMP--/entities)--FIX-- receptor] receptors] at the glycine co-agonist site, providing protection against excitotoxicity
- An antagonist of the α7 nicotinic acetylcholine receptor, modulating [cholinergic] neurotransmission
- A ligand of the aryl hydrocarbon receptor (AHR), influencing immune regulation
- An antioxidant that scavenges reactive oxygen species
KYNA levels are generally reduced in neurodegenerative diseases, reflecting a shift of the pathway toward the neurotoxic branch [4][5].
¶ The Neurotoxic Branch: 3-Hydroxykynurenine and Quinolinic Acid
The alternative metabolic route involves hydroxylation of L-kynurenine by kynurenine 3-monooxygenase (KMO) to yield 3-hydroxykynurenine (3-HK). This pathway proceeds predominantly in [microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--[6]:
- 3-Hydroxykynurenine (3-HK): A potent generator of reactive oxygen species through auto-oxidation. 3-HK induces neuronal apoptosis via oxidative stress mechanisms, damages [mitochondria[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics--TEMP--/entities)--FIX--, and enhances vulnerability to excitotoxic insult [7].
- 3-Hydroxyanthranilic acid (3-HAA): Downstream metabolite of 3-HK via kynureninase; has both pro-oxidant and immunomodulatory properties. 3-HAA inhibits T cell proliferation and induces apoptosis in immune cells [7].
- Quinolinic acid (QUIN): The terminal neurotoxic metabolite, produced from 3-HAA by 3-hydroxyanthranilic acid oxygenase (3-HAO). Quinolinic acid is a selective agonist of [NMDA receptor[/entities/[nmda-receptor[/entities/[nmda-receptor[/entities/[nmda-receptor--TEMP--/entities)--FIX-- receptor] receptors] containing GluN2A and GluN2B subunits, causing excitotoxic neuronal damage. QUIN also promotes tau] hyperphosphorylation], generates reactive oxygen species, inhibits glutamate uptake by [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX--, and disrupts the [Blood-Brain Barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX-- [5].
A critical feature of the kynurenine pathway in the brain is its cell-type compartmentalization:
- [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX-- express KATs but lack KMO, preferentially producing neuroprotective KYNA
- **[microglia[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX--" title="[Tryptophan Metabolism and Neurodegeneration: Longitudinal Associations of Kynurenine Pathway Metabolites with Cognitive Performance and Plasma AD Biomarkers. J Alzheimers Dis (2023]. PubMed)">8
In [Down syndrome-associated Alzheimer's Disease], kynurenine pathway metabolite alterations have also been documented, with elevated QUIN/KYNA ratios correlating with cognitive decline [9].
In [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, kynurenine pathway dysregulation contributes to [dopaminergic neurodegeneration[/mechanisms/[dopaminergic-neurodegeneration[/mechanisms/[dopaminergic-neurodegeneration[/mechanisms/[dopaminergic-neurodegeneration--TEMP--/mechanisms)--FIX--:
- 3-HK and QUIN promote oxidative damage in [dopaminergic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--[neurons[/[microglial[/[microglial[/[microglial[/microglial inflammatory signatures in ALS tissue [12]
Kynurenine 3-monooxygenase (KMO) is the most actively pursued therapeutic target within the kynurenine pathway. Inhibiting KMO:
- Blocks formation of neurotoxic 3-HK and downstream QUIN
- Shunts kynurenine metabolism toward neuroprotective KYNA production
- Brain-penetrant KMO inhibitors have shown efficacy in preclinical models of HD, AD, and stroke [13]
Several classes of KMO inhibitors have been developed:
- Ro 61-8048: Early prototype that demonstrated neuroprotection in HD mouse models but has limited brain penetrance
- CHDI-340246: Optimized for brain exposure; reduces 3-HK and elevates KYNA in rodent brains
- GSK065/GSK366: Clinical-stage KMO inhibitors developed for peripheral indications, with potential repurposing for neurodegeneration [18][19]
IDO1 inhibitors, originally developed for immuno-oncology (e.g., epacadostat, navoximod), could theoretically reduce overall kynurenine pathway flux during neuroinflammation. However, their application in neurodegeneration is complicated by IDO1's dual role in immune regulation—inhibiting IDO1 may exacerbate autoimmune components of disease [2].
¶ KYNA Analogs and Prodrugs
Strategies to boost neuroprotective KYNA include:
- Synthetic KYNA analogs with improved Blood-Brain Barrier penetrance
- KAT enzyme activators to enhance endogenous KYNA production
- Prodrug approaches that release KYNA in brain tissue [1]
Physical exercise acts as a "kynurenine sink" through induction of kynurenine aminotransferases (KATs) in skeletal muscle. Exercise-induced KAT expression:
- Converts circulating kynurenine to KYNA in the periphery
- Reduces brain kynurenine uptake (kynurenine crosses the Blood-Brain Barrier; KYNA does not)
- Mitigates excitotoxicity and neuroinflammation centrally
- May partly explain the neuroprotective effects of exercise in neurodegenerative diseases [15]
¶ Kynurenine Pathway and Cerebral Small Vessel Disease
Recent evidence from the Maastricht Study (2025) links kynurenine pathway metabolites to markers of neurodegeneration and [cerebral small vessel disease[/diseases/[cerebral-small-vessel-disease[/diseases/[cerebral-small-vessel-disease[/diseases/[cerebral-small-vessel-disease--TEMP--/diseases)--FIX--. Higher kynurenine/tryptophan ratios and elevated 3-HK are associated with white matter hyperintensities and brain atrophy, suggesting that KP dysregulation may contribute to [Vascular Dementia[/diseases/[vascular-dementia[/diseases/[vascular-dementia[/diseases/[vascular-dementia--TEMP--/diseases)--FIX-- pathogenesis through endothelial damage and [BBB[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX-- dysfunction [16].
Key research priorities include:
- Development of brain-penetrant KMO inhibitors suitable for chronic dosing in neurodegenerative diseases
- Validation of KP metabolites (QUIN/KYNA ratio, 3-HK levels) as prognostic [biomarkers] across disease stages
- Understanding the interaction between [gut microbiome]-derived tryptophan metabolites and brain KP activity
- Elucidation of the role of the AHR (aryl hydrocarbon receptor) as an integrator of KP signaling in neuroinflammation
- Investigation of combination approaches targeting multiple KP nodes simultaneously
- Clinical trials of KMO inhibitors in neurodegenerative disease populations
- [All Mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/mechanisms
The study of Kynurenine Pathway In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [Modulation of the Kynurenine Pathway: A New Approach for Treating Neurodegeneration. Life 16(2]:266 (2025). MDPI)
- [Kynurenine Pathway: a possible new mechanism for exercise in the prevention and treatment of Alzheimer's Disease. Front Aging Neurosci (2025]. Frontiers)
- [Kynurenine Metabolism and Alzheimer's Disease: The Potential Targets and Approaches. Neurochem Res (2022]. Springer)
- [Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease: A systematic review and meta-analysis. Front Immunol (2022]. Frontiers)
- [The Role of Tryptophan Dysmetabolism and Quinolinic Acid in Depressive and Neurodegenerative Diseases. Biomolecules 12(7]:998 (2022). MDPI)
- [Tryptophan Metabolism Through the Kynurenine Pathway in Glial Cells. Neuroglia 6(1]:14 (2025). MDPI)
- [Therapeutic potential of targeting kynurenine pathway in neurodegenerative diseases. Eur J Med Chem (2023]. ScienceDirect)
- [Tryptophan Metabolism and Neurodegeneration: Longitudinal Associations of Kynurenine Pathway Metabolites with Cognitive Performance and Plasma AD Biomarkers. J Alzheimers Dis (2023]. PubMed)
- [Kynurenine pathway metabolite alterations in Down syndrome and Alzheimer's Disease. Alzheimers Dement (2025]. Wiley)
- [Kynurenine Pathway Dysregulation in Parkinson's Disease: Insights for Disease Modulation and Therapy. Neurotox Res (2025]. SAGE)
- [Kynurenine Pathway Modulation by Exercise in Multiple Sclerosis: Implications for Neuroprotection and Inflammation. Cell Mol Neurobiol (2025]. Springer)
- [Kynurenines and Mitochondrial Disturbances in Multiple Sclerosis. Int J Mol Sci 26(11]:5098 (2025). MDPI)
- [Advantages of brain penetrating inhibitors of kynurenine-3-monooxygenase for treatment of neurodegenerative diseases. J neuroinflammation (2021]. PMC)
- [A brain-permeable inhibitor of the neurodegenerative disease target kynurenine 3-monooxygenase prevents accumulation of neurotoxic metabolites. Commun Biol (2019]. Nature)
- [Kynurenine Pathway Metabolites as Mediators of Exercise-Induced Mood Enhancement, Fatigue Resistance, and Neuroprotection. Int J Mol Sci 27(1]:129 (2025). MDPI)
- [The kynurenine pathway and markers of neurodegeneration and cerebral small vessel disease: The Maastricht Study. J Neurol Sci (2025]. JNS
🟡 Moderate Confidence
| Dimension |
Score |
| Supporting Studies |
16 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
33% |
| Mechanistic Completeness |
50% |
Overall Confidence: 44%